- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01545830
Metabolic Syndrome and Insulin Resistance at Allina (MISURA)
Randomized, Controlled Trial of Vitamin D Replenishment in Metabolic Syndrome
Vitamin D deficiency is widespread and appears to represent one easily and inexpensively modifiable risk factor for diabetes and cardiovascular disease. More than 40 years of data link hypovitaminosis D to metabolic syndrome, insulin resistance, hyperglycemia, type 2 diabetes and increased cardiovascular risk.
Screening for vitamin D deficiency followed by supplementation in appropriate individuals could be among the simplest and most cost-effective measures for reducing metabolic syndrome and insulin resistance in the general population.
This study will test the hypothesis that increasing vitamin D status in vitamin D deficient individuals with metabolic syndrome will:
- reduce multiple serum cardiometabolic risk factors for both diabetes and cardiovascular disease,
- stabilize or reverse the stage of pre-diabetes,
- improve quality of life, and,
- improve the ability to make health-related behavioral changes.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Longitudinal observational studies suggest a significant inverse association between vitamin D status and both incident and prevalent metabolic syndrome/type II diabetes. Results from small underpowered trials and post-hoc analyses of data from larger trials designed for bone-specific outcomes suggest that vitamin D may slow the progression to diabetes in adults with glucose intolerance. However, at this time, no randomized trials of sufficient size exist to assess effectiveness.
Importantly, in the investigators' own study of over 10,000 Allina employees, the investigators found that 6% of these employees had levels less than 10 ng/mL, 30% less than 20 ng/ml and 60% less than 30 ng/ml. Recently, the Intermountain Heart Collaborative Study Group reviewed 41,504 patient records with at least one measured vitamin D level. Surprisingly, both the Intermountain and the Allina Employee study demonstrate vitamin D deficiency (≤30 ng/ml) in more than 60% of people tested with only minor differences by gender or age (Plotnikoff GA, Finch M, Dusek JA. Impact of Vitamin D Deficiency on the Productivity of a Health Care Workforce. J Occup Environ Med (in press)).
Furthermore, the Intermountain group demonstrated that vitamin D levels less than 30 ng/ml, compared to levels greater than 30 ng/ml, were associated with highly significant (p <0.0001) increases in the prevalence of diabetes, hypertension, hyperlipidemia, and peripheral vascular disease. Also, those without risk factors but with severe deficiency had an increased likelihood of developing diabetes, hypertension, and hyperlipidemia. The vitamin D levels were also highly associated with coronary artery disease, myocardial infarction, heart failure, and stroke (all p <0.0001), as well as with incident death, heart failure, coronary artery disease/myocardial infarction (all p <0.0001), stroke (p = 0.003), and their composite (p <0.0001).
Numerous prevention efforts are underway to minimize the predicted economic and human burdens from these increasingly common diseases. However, few, if any, prospective clinical trials are underway with vitamin D interventions. This trial is specifically designed to prospectively test the impact of vitamin D replenishment on both metabolic syndrome and insulin resistance.
The 2011 Endocrine Society guidelines assert that vitamin D intakes above the current recommendations may be associated with better health outcomes. However, there is no consensus on the optimal 25(OH)D concentration necessary to minimize metabolic syndrome, insulin resistance and progression to diabetes. This trial is designed to prospectively identify optimal serum levels for reduction of cardiometabolic risk factors.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Allina Health
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Please Note: All participants must be an employee of Allina Health or the spouse of an Allina employee.
Inclusion Criteria:
- Vitamin D deficiency, defined as 25-OH vitamin D ≤ 25 ng/ml
- Metabolic syndrome as defined by more than three or more of the following:
Elevated waist circumference
- Men - Equal to or greater than 40 inches
- Women - Equal to or greater than 35 inches
- Elevated serum triglycerides (≥150 mg/dL)
- Men - Less than 40 mg/dL
- Women - Less than 50 mg/dL
- Elevated blood pressure (≥130/85 or use of medication for hypertension)
- Elevated fasting glucose (≥100 mg/dL or use of medication for hyperglycemia)
Exclusion Criteria:
- Known cardiovascular disease defined as current or prior coronary heart disease, stroke/transient ischemic attack, heart failure, or peripheral vascular disease.
- During the study, addition of any medications known to change outcome measures including medications or supplements for hyperlipidemia, hypertension, weight loss, diabetes.
- Current Vitamin D supplementation beyond that found in a multivitamin (400 IU)
- Current calcium supplementation greater than 600 mg
- Untreated blood pressure greater than 159/99 at baseline
- Treated blood pressure greater than 150/90 at baseline
- Any condition which could limit the ability to complete and comply with 6-month study
- Unwillingness or inability to comply with study requirements
- Known allergy to coconut or coconut oil
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Regular Dose
Intervention: 600 IUs of cholecalciferol taken by mouth daily.
|
Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Andre navne:
|
Eksperimentel: High Dose D
Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
|
Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
insulin resistance score by NMR lipid fractionation
Tidsramme: 6 months
|
additional insulin resistance measure
|
6 months
|
Reynolds Risk Score
Tidsramme: 6 months
|
The Reynolds Risk Score is designed to predict one's risk of having a future heart attack, stroke, or other major heart disease in the next 10 years.
In addition to your age, blood pressure, cholesterol levels and whether you currently smoke, the Reynolds Risk Score uses information from two other risk factors, a blood test called hsCRP (a measure of inflammation) and whether or not either of your parents had a heart attack before they reached age 60 (a measure of genetic risk).
|
6 months
|
Pre-diabetes stage
Tidsramme: 6 months
|
The pre-diabetes stage, a marker of progression toward type 2 diabetes mellitus, is a calculated score based upon results of fasting adiponectin, insulin and proinsulin.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
blodtryk
Tidsramme: 6 måneder
|
6 måneder
|
|
vægt
Tidsramme: 6 måneder
|
6 måneder
|
|
25-OH-vitamin D
Tidsramme: 6 months
|
25-OH-vitamin D is the best measure of vitamin D status.
|
6 months
|
fasting lipid profile
Tidsramme: 6 months
|
6 months
|
|
adiposity markers
Tidsramme: 6 months
|
Adiponectin: This adipocyte-derived protein increases hepatic and peripheral insulin sensitivity, moderates fat tissue growth, decreases lipid and glucose production in the liver and suppresses vascular inflammation. This measure declines as insulin resistance increases. Leptin: This adipocyte-derived hormone plays a key role in regulating neuroendocrine and immune function, appetite, metabolic rate and body weight. Many overweight individuals have elevated levels and leptin resistance. |
6 months
|
TNF-alpha
Tidsramme: 6 months
|
Inflammatory markers: TNF-alpha, IL-6, IL-8.
These inflammatory mediators are central to the pathophysiology of obesity and its systemic effects
|
6 months
|
PROMIS-29
Tidsramme: 6 months
|
PROMIS is a questionnaire data bank developed and made available by the National Institutes of Health for research purposes.
It is used to measure the core domains of physical functioning, fatigue, pain, depression, anxiety, and social role participation.
|
6 months
|
Perceived Stress Scale (PSS)
Tidsramme: 6 months
|
The PSS is brief, validated and widely used psychological instrument for assessing a participant's perception of stress.
The PSS-4 consists of 4 questions to measure the degree to which situations in the participant's life are perceived as stressful including questions related to perceived unpredictability and lack of control.
|
6 months
|
WPAI
Tidsramme: 6 months
|
This 6 item, validated instrument measures work and general activity impairment due to health problems.
It uses a seven day recall and has been adapted for use in populations with differing health problems.
|
6 months
|
PROMIS-GH
Tidsramme: 6 months
|
PROMIS is a questionnaire data bank developed and made available by the National Institutes of Health for research purposes.
The PROMIS-GH consists of 10 items, representing multiple domains and can be scored into a Global Physical Health component and a Global Mental Health component
|
6 months
|
International Physical Activity Questionnaire (IPAQ)
Tidsramme: 6 months
|
The International Physical Activity Questionnaire (IPAQ) short form (4 generic items) versions for use by either telephone or self-administered methods are available.
The purpose of the questionnaire is to provide a common instrument that can be used to obtain internationally comparable data on health related physical activity.
The development of this international measure for physical activity commenced in Geneva in 1998 and was followed by extensive reliability and validity testing undertaken in 12 countries (14 sites) across 6 continents during 2000.
|
6 months
|
IL-6
Tidsramme: 6 months
|
Inflammatory mediators, including IL-6, are central to the pathophysiology of obesity and its systemic effects.
|
6 months
|
IL-8
Tidsramme: 6 months
|
Inflammatory mediators, inlcuding IL-8, are central to the pathophysiology of obesity and its systemic effects.
|
6 months
|
HS-CRP
Tidsramme: 6 months
|
Elevated HS-CRP predicts the development of type II diabetes and is a crucial factor in calculating the Reynolds Risk Score.
|
6 months
|
Lp-PLA2 (PLAC)
Tidsramme: 6 months
|
This is an enzyme produced by inflammatory cells that hydrolyzes oxidized phospholipids in HDL and catalyzes the degradation of PAF, platelet activating factor.
Levels are positively correlated with increased risk of developing coronary artery disease and stroke.
|
6 months
|
PAI-1
Tidsramme: 6 months
|
This is the primary inhibitor of plasminogen activation.
Elevated levels predispose to clot formation by inhibiting fibrinolytic activity.
|
6 months
|
Fibrinogen
Tidsramme: 6 months
|
Fibrinogen is also known as coagulation Factor I. Elevated levels are associated with cardiovascular disease.
This is an acute-phase protein that is elevated in any form of inflammation.
|
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Gregory Plotnikoff, MD, Allina Health
- Studieleder: Jeffery Dusek, PhD, Allina Health
- Studieleder: Shaina Biron, Allina Health
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Glukosemetabolismeforstyrrelser
- Metaboliske sygdomme
- Sygdom
- Hyperinsulinisme
- Syndrom
- Metabolisk syndrom
- Insulin resistens
- Lægemidlers fysiologiske virkninger
- Mikronæringsstoffer
- Vitaminer
- Knogletæthedsbevarende midler
- Calciumregulerende hormoner og midler
- D-vitamin
- Cholecalciferol
Andre undersøgelses-id-numre
- SPA ID 3607
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Metabolisk syndrom
-
Grand Valley State UniversityTilmelding efter invitationMetabolic Associated-dysfunction Steatotic Lever Disease (MASLD) | Metabolic Associated-dysfunction Steatohepatitis (MASH)Forenede Stater
-
Scripps Whittier Diabetes InstituteAfsluttetCardio-metabolic Care-Team Intervention (CMC-TI)
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ikke rekrutterer endnuPrædiabetes | Kontinuerlig glukoseovervågning | Metabolic Management Center
-
University of Colorado, DenverRekrutteringKlinefelters syndrom | Trisomi X | XYY syndrom | XXXY og XXXXY syndrom | Xxyy syndrom | Xyyy syndrom | Xxxx syndrom | Xxxxx syndrom | Xxxyy syndrom | Xxyyy syndrom | Xyyyy syndrom | Mand med sexkromosommosaicismeForenede Stater
-
Riphah International UniversityAfsluttet
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
Kliniske forsøg med vitamin D3 (cholecalciferol)
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Aktiv, ikke rekrutterende
-
Medical University of South CarolinaThrasher Research FundAfsluttetD-vitamin mangel | GraviditetForenede Stater
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbejdspartnereAfsluttet
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Afsluttet
-
University of California, San FranciscoAfsluttetColitis ulcerosa (UC) | Crohns sygdom (CD)Forenede Stater
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceAfsluttetSystemisk lupus erythematosusForenede Stater
-
Atlanta VA Medical CenterAfsluttetD-vitamin mangel | Kronisk nyresygdomForenede Stater
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)AfsluttetCystisk fibrose | Allergisk bronkopulmonal aspergilloseForenede Stater
-
Rashid Centre for Diabetes and ResearchAfsluttetFedme | Type 2 diabetes mellitus | Hypovitaminose DForenede Arabiske Emirater
-
Sanjay Gandhi Postgraduate Institute of Medical...AfsluttetPancreatitis, kroniskIndien